000			02321 a2200673 4500
005			20250513031309.0
264		0	_c19950117
008			199501s 0 0 eng d
022			_a0006-4971
040			_aNLM _beng _cNLM
100	1		_aClift, R A
245	0	0	_aMarrow transplantation for patients in accelerated phase of chronic myeloid leukemia. _h[electronic resource]
260			_bBlood _cDec 1994
300			_a4368-73 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.; Review
650	0	4	_aAcute Disease
650	0	4	_aAdult
650	0	4	_aBone Marrow Transplantation _xmortality
650	0	4	_aBusulfan _xadministration & dosage
650	0	4	_aCause of Death
650	0	4	_aChild
650	0	4	_aCombined Modality Therapy
650	0	4	_aCyclophosphamide _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aGraft vs Host Disease _xprevention & control
650	0	4	_aGranulocyte Colony-Stimulating Factor _xtherapeutic use
650	0	4	_aGranulocyte-Macrophage Colony-Stimulating Factor _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aImmunologic Factors _xtherapeutic use
650	0	4	_aInfections _xetiology
650	0	4	_aInterferons _xtherapeutic use
650	0	4	_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy
650	0	4	_aLeukemia, Myeloid, Accelerated Phase _xmortality
650	0	4	_aLife Tables
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMultivariate Analysis
650	0	4	_aPrognosis
650	0	4	_aRecombinant Proteins _xtherapeutic use
650	0	4	_aRetrospective Studies
650	0	4	_aSalvage Therapy
650	0	4	_aSpleen _xpathology
650	0	4	_aSplenectomy
650	0	4	_aSurvival Analysis
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aWashington _xepidemiology
650	0	4	_aWhole-Body Irradiation _xadverse effects
700	1		_aBuckner, C D
700	1		_aThomas, E D
700	1		_aBryant, E
700	1		_aAnasetti, C
700	1		_aBensinger, W I
700	1		_aBowden, R
700	1		_aDeeg, H J
700	1		_aDoney, K C
700	1		_aFisher, L D
773	0		_tBlood _gvol. 84 _gno. 12 _gp. 4368-73
999			_c7527138 _d7527138